Dr. Michelle McMurry-Heath will become BIO’s President and CEO on June 1, 2020

After a comprehensive search, the Biotechnology Innovation Organization (BIO) has announced that Michelle McMurry-Heath, MD, PhD, as its incoming President and CEO.  McMurry-Heath will become the organization’s next President and CEO on June 1, 2020. 

BIO is the world’s largest science and public advocacy organization, representing 1,000 members.  McMurry-Heath will succeed former Rep. Jim Greenwood, who has led the organization since 2005 and BIO’s founding President & CEO Carl B. Feldbaum who served from 1993 to  2004.Continue reading

C-Path and Provention Bio Announce Data Sharing Collaboration to Develop Advanced Drug Development Tools in Type 1 Diabetes


TUCSON, Ariz., and OLDWICK, N.J. May 13, 2020 — The Critical Path Institute (C-Path) and Provention Bio, Inc. (Nasdaq: PRVB) are proud to announce their collaboration to significantly improve the scientific community’s insight into type 1 diabetes (T1D) through Provention’s contribution of data from the Phase III Protégé study of teplizumab to the T1D Trial Outcome Measures Initiative (TOMI) integrated database. The Protégé study evaluated teplizumab on the preservation of beta cell function in newly onset T1D patients and generated the largest disease modifying interventional clinical trial dataset in T1D with more than 500 patients.Continue reading

Biotechnology Innovation Organization Launches New Medicine Pipeline Tracker Illustrates Unprecedented Effort to Eradicate COVID-19

Washington, DC (May 12, 2020) – The Biotechnology Innovation Organization (BIO) today unveiled a first-of-its-kind, interactive tracker of the new treatments and vaccines in the COVID-19 pipeline. This online resource illustrates the unprecedented campaign being undertaken by biopharmaceutical innovators to combat – and ultimately eradicate – the novel coronavirus. Continue reading

AdvaMed Issues MedTech Compliance Guidance For COVID-19 Response

WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) today announced availability of a newly created “Code of Ethics Compliance Guidance Related to the COVID-19 Response.”

“This guidance seeks to help AdvaMed members and other medical technology companies develop and implement processes that both support rapid decision-making in the context of the pandemic and mitigate any related compliance risks,” said Christopher L. White, AdvaMed COVID action team leader, chief operating officer and general counsel.Continue reading